Metraipolis › archive › dc_ae615e667a75

Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the… — Europe PMC PMID:42371147

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42371147
DOI
10.1007/s00415-[numero omesso]-5
License (as archived)
solo-consultazione
Archived
2026-10-31T07:12:18.137Z
SHA-256 of the archived text
4883ab9826220b8afc326985f2aa0deac699b3d95f47a81d1ae2ae41d240f43a
Stable URL of this page
https://metraipolis.com/documento/dc_ae615e667a75

How to cite

Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the… — Europe PMC PMID:42371147 — Europe PMC (en), https://europepmc.org/article/MED/42371147 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ae615e667a75 (Metraipolis archive dc_ae615e667a75, sha256 4883ab9826220b8afc326985f2aa0deac699b3d95f47a81d1ae2ae41d240f43a)
BibTeX
@misc{dcae615e667a75,
  title = {Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the… — Europe PMC PMID:42371147},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42371147},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ae615e667a75; sha256 4883ab9826220b8afc326985f2aa0deac699b3d95f47a81d1ae2ae41d240f43a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42371147. Agents can read the archived copy with the MCP tool read_document.